Mirati Therapeutics, Inc. (MRTX): Price and Financial Metrics
MRTX Price/Volume Stats
| Current price | $58.70 | 52-week high | $64.41 |
| Prev. close | $58.80 | 52-week low | $27.30 |
| Day low | $58.54 | Volume | 20,994,400 |
| Day high | $58.99 | Avg. volume | 2,758,857 |
| 50-day MA | $57.69 | Dividend yield | N/A |
| 200-day MA | $45.47 | Market Cap | 4.12B |
MRTX Stock Price Chart Interactive Chart >
Mirati Therapeutics, Inc. (MRTX) Company Bio
Mirati Therapeutics develops molecularly targeted cancer treatments that are intended to inhibit tumor growth. The company was founded in 1995 and is based in San Diego, California.
Latest MRTX News From Around the Web
Below are the latest news stories about MIRATI THERAPEUTICS INC that investors may wish to consider to help them evaluate MRTX as an investment opportunity.
FDA Rejects Amgen's (AMGN) NDA Seeking Full Nod for LumakrasPer the FDA, Amgen (AMGN) will need to complete an additional confirmatory study on Lumakras in certain lung cancer patients before February 2028 to secure full approval. |
Mirati Therapeutics Inc EVP & Chief Scientific Officer Jamie Christensen Sells 2,387 SharesOn December 18, 2023, Jamie Christensen, EVP & Chief Scientific Officer of Mirati Therapeutics Inc (NASDAQ:MRTX), executed a sale of 2,387 shares in the company. |
Insider Sell Alert: EVP Benjamin Hickey Sells Shares of Mirati Therapeutics Inc (MRTX)In a recent transaction on December 13, 2023, Benjamin Hickey, the Executive Vice President and Chief Commercial Officer of Mirati Therapeutics Inc (NASDAQ:MRTX), sold 2,220 shares of the company. |
Billionaire Joe Lewis Keeps Trading Stocks Behind US Insider-Trading Charges(Bloomberg) -- Joe Lewis, the British billionaire behind one of the world’s biggest investing fortunes, continues to buy and sell stocks at the center of US insider-trading allegations against him.Most Read from BloombergJPMorgan Is in a Fight Over Its Client’s Lost $50 Million FortuneGoldman Trader Paid $100 Million Since 2020 Is Stepping DownArgentina’s Milei Devalues Peso by 54% in First Batch of Shock MeasuresNetflix Posts Viewer Data on Every Show, Film for First TimeRaimondo Vows ‘Stronges |
3 Resilient Stocks with Massive Potential to Boost Your WealthThese three stocks with massive potential can make patient investors fabuslously wealthy as they come roaring back to life. |
MRTX Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | 6.01% |
| 1-year | 35.72% |
| 3-year | -62.29% |
| 5-year | -7.82% |
| YTD | -0.09% |
| 2023 | 29.66% |
| 2022 | -69.11% |
| 2021 | -33.21% |
| 2020 | 70.45% |
| 2019 | 203.77% |
Continue Researching MRTX
Want to see what other sources are saying about Mirati Therapeutics Inc's financials and stock price? Try the links below:Mirati Therapeutics Inc (MRTX) Stock Price | Nasdaq
Mirati Therapeutics Inc (MRTX) Stock Quote, History and News - Yahoo Finance
Mirati Therapeutics Inc (MRTX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...